Render Target: SSR
Render Timestamp: 2025-01-30T18:44:29.785Z
Commit: 1bba917eefc12d62e72a522121e2774ffbd0ee36
XML generation date: 2024-09-30 01:55:42.825
Product last modified at: 2025-01-12T15:45:08.152Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

HHLA2/B7-H7 (E1U6X) Rabbit mAb #52200

Filter:
  • WB

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 70-80
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    HHLA2/B7-H7 (E1U6X) Rabbit mAb recognizes endogenous levels of total HHLA2/B7-H7 protein.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Asn101 of human HHLA2/B7-H7 protein.

    Background

    HERV-H LTR-associating protein 2 (HHLA2, with alternative names of B7-H5 and B7-H7) is a member of the B7 immunoglobulin superfamily (1). HHLA2 protein is constitutively expressed on the surface of human monocytes and is induced on B cells after stimulation with LPS and IFN-γ (1,2). Through interaction with TMIGD2, which is constitutively expressed on all naïve T cells and the majority of natural killer cells, but not on T regulatory cells or B cells, HHLA2 co-stimulates T cells in the context of TCR-mediated activation, enhancing T cell proliferation and cytokine production via an AKT-dependent signaling cascade (2). Contrary to this, HHLA2 has also been shown to inhibit T cell proliferation and cytokine production, suggesting a secondary receptor for HHLA2 that is expressed on activated T cells with co-inhibitory functions (3). Moreover, HHLA2 has been shown to be highly expressed in various types of cancer, and is associated with a poor prognosis (4-10). Further understanding the immunologic functions of the HHLA2 pathway will guide the selection of agents used for cancer immunotherapy, autoimmune disorders, infection, and transplant rejection.
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.